Ho-Yi Biotech's topical cream Bonvadis approved for sale in Thailand
Ho-Yi Biotech announced that its topical cream Bonvadis has received marketing approval from the Thai Food and Drug Administration (ThaiFDA) for full wound indication as a medical device. This approval allows the product to be sold in the Thai market, where the company aims to expand its business in diabetic wound care.
📋 Article Processing Timeline
- 📰 Published: May 6, 2026 at 20:23
- 🔍 Collected: May 6, 2026 at 20:31 (8 min after Published)
- 🤖 AI Analyzed: May 6, 2026 at 20:34 (2 min after Collected)
ASEAN Finance Special Report (Total 300 articles)
Central News Agency
nắm bắt新南向，放眼東協經濟脈動。中央社「東南亞財經資訊專網」每日為您精選多則泰國、越南、印尼、馬來西亞、菲律賓等國的財經頭條。無論是政府新政、產業動向或投資商機，讓您即時掌握關鍵資訊，洞悉市場，搶占商機。
(Central News Agency, Taipei 6th) Ho-Yi Biotech Co., Ltd. announced today that its topical cream Bonvadis has obtained marketing approval for medical devices with full wound indication from the Thai Food and Drug Administration (ThaiFDA). Ho-Yi stated that upon market launch and sale, it will pay royalties to the licensor according to the licensing agreement within the specified period.
Ho-Yi stated that it received notification from its registration agent that the topical cream Bonvadis has obtained marketing approval for medical devices with full wound indication from the Thai Food and Drug Administration, with marketing approval certificate number 69-2-2-2-0004267, permitting its sale in Thailand.
Ho-Yi pointed out that according to statistics from the International Diabetes Federation (IDF), Thailand has approximately 6.36 million diabetic patients, with an annual wound care burden exceeding 700 million US dollars.
Ho-Yi explained that its global commercialization strategy for wound care products adopts a dual-channel entry approach for pharmaceuticals and medical devices. Based on the medical burden in various countries worldwide, it systematically applies for market entry in each country and simultaneously carries out international commercialization through its international business division. 1150506
Stand with facts, every sponsorship from you is a power to protect press freedom.
Download CNA's "First-hand News" APP to get the latest news instantly.
All text, images, and videos on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.
Central News Agency
nắm bắt新南向，放眼東協經濟脈動。中央社「東南亞財經資訊專網」每日為您精選多則泰國、越南、印尼、馬來西亞、菲律賓等國的財經頭條。無論是政府新政、產業動向或投資商機，讓您即時掌握關鍵資訊，洞悉市場，搶占商機。
(Central News Agency, Taipei 6th) Ho-Yi Biotech Co., Ltd. announced today that its topical cream Bonvadis has obtained marketing approval for medical devices with full wound indication from the Thai Food and Drug Administration (ThaiFDA). Ho-Yi stated that upon market launch and sale, it will pay royalties to the licensor according to the licensing agreement within the specified period.
Ho-Yi stated that it received notification from its registration agent that the topical cream Bonvadis has obtained marketing approval for medical devices with full wound indication from the Thai Food and Drug Administration, with marketing approval certificate number 69-2-2-2-0004267, permitting its sale in Thailand.
Ho-Yi pointed out that according to statistics from the International Diabetes Federation (IDF), Thailand has approximately 6.36 million diabetic patients, with an annual wound care burden exceeding 700 million US dollars.
Ho-Yi explained that its global commercialization strategy for wound care products adopts a dual-channel entry approach for pharmaceuticals and medical devices. Based on the medical burden in various countries worldwide, it systematically applies for market entry in each country and simultaneously carries out international commercialization through its international business division. 1150506
Stand with facts, every sponsorship from you is a power to protect press freedom.
Download CNA's "First-hand News" APP to get the latest news instantly.
All text, images, and videos on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.